Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
Founded over 30 years ago, MPM BioImpact is a biotechnology investment firm based in the United States. The firm manages over $3 billion in assets under management (AUM) across various funds, including early-stage venture funds and public equities. MPM focuses on building and investing in companies involved in drug development.
MPM BioImpact invests in both private and public companies engaged in the drug development process, targeting transformative therapies for patients. Their investment strategy spans pre-seed to Series C stages, primarily within the biotech and healthcare sectors. The firm employs the BIOIMPACT FUND™, which specifically seeks companies that aim to improve patient outcomes.
Notable portfolio companies include Orna Therapeutics, which develops coding RNA medicines using circular RNA technology; Aktis Oncology, focused on alpha radio-pharmaceuticals for solid tumors; Reunion Neuroscience, innovating psychedelic-inspired pharmaceuticals for mental health disorders; and argenx, known for its lead drug VYVGART addressing serious autoimmune diseases.
Submit your pitch through their form at mpmcapital.com.
As of October 2023: MPM BioImpact has been active in the biotechnology space, with recent highlights including FDA designations for Aktis Oncology and Reunion Neuroscience, as well as the acquisition of Orna Therapeutics by Lilly.
Yes, MPM BioImpact often leads investment rounds, particularly in early-stage biotech companies.
The firm is open to follow-on investments, especially for companies that demonstrate significant progress and potential in their drug development.
MPM BioImpact manages over $3 billion in assets across various funds, focusing on biotechnology and healthcare investments.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.